Progress in drug therapy for multiple myeloma

Article

DOI: 10.1007/s11805-008-0251-8

Cite this article as:
Yang, S. & Zhao, B. Chin. J. Clin. Oncol. (2008) 5: 251. doi:10.1007/s11805-008-0251-8
  • 13 Downloads

Abstract

Multiple myeloma remains incurable with conventional treatments. However, new active drugs, including the immunomodulatory agents, thalidomide and lenalidomide, and the proteasome inhibitors bortezomib and NPI-0052, and other targeted therapies, have shown promising anti-myeloma activity. These agents represent a new generation of treatments for multiple myeloma that affect both specific intracellular signaling pathways and the tumor microenvironment. This review therefore focuses on the extensive clinical data available from studies of these drugs in the treatment of newly diagnosed, refractory and relapsed multiple myeloma.

Key Words

multiple myeloma therapy immunomodulatory proteasome inhibitor targeted therapies 

Copyright information

© Tianjin Medical University Cancer Institute and Hospital and Springer-Verlag GmbH 2008

Authors and Affiliations

  1. 1.Department of Medical OncologyTumor Hospital of Xinjiang Medical UniversityUrumqiChina

Personalised recommendations